Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000078550
Ethics application status
Approved
Date submitted
19/01/2015
Date registered
29/01/2015
Date last updated
25/09/2015
Type of registration
Retrospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of ibuprofen sustained release tablet against the innovator ibuprofen tablet conducted under fasting conditions and at steady state in healthy male and female volunteers
Scientific title
A multiple dose, randomized, blinded, bioequivalence study of ibuprofen sustained release tablets in a 2 way crossover comparison against the innovator ibuprofen tablet conducted under fasting conditions and at steady state in healthy male and female volunteers
Secondary ID [1] 285995 0
None
Universal Trial Number (UTN)
U1111-1162-1817
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bioequivalence study conducted in healthy volunteers comparing two formulations of ibuprofen with no health condition or problem studied.

Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, ibuprofen belongs to a class of medicines called nonsteroidal anti-inflammatory drugs (NSAIDS). It is used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, arthritis of the spine, swollen joints, frozen shoulder, bursitis, tendinitis, tenosynovitis, lower back pain, sprains and strains. It can also be used to treat other painful conditions such as toothache, pain after operations, period paid and headache, including migraine. 293954 0
Condition category
Condition code
Other 294251 294251 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Multiple dose, crossover over study design whereby each participant receives the test formulation of ibuprofen (1 x 800 mg) on five occasions and the innovator formulation of ibuprofen (1 x 800 mg) on five occasions with each dose seperated by a 10 day washout period. The intervention for this trial is the test formulation of ibuprofen.

On study days 1-5 subjects will receive 5 daily doses of one formulation (either the test or innovator) and on study days 15-19 they will receive 5 daily doses of the other formulation (either the innovator or test).

Each dose (1 x 800 mg) will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.

Participants are required not to eat for 10 hours before receiving each dose.

On study days 1 to 4 and 15 to 18 subjects will report to Zenith Technology for dosing and the provision of one blood sample. They will then be given a light breakfast to consume following each dose at home.

On study day 5 and 19 no water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose) and are required to fast for approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance can be monitored and for 24 hours after dosing.
Intervention code [1] 290974 0
Treatment: Drugs
Comparator / control treatment
Mulitple dose, crossover over study design whereby each participant receives the test formulation of ibuprofen (1 x 800 mg sustained release) on five occasions and the innovator formulation of ibuprofen (1 x 800 mg sustained release) on five occasion with each dose seperated by a 10 day washout period. The comparator/control for this trial is the innovator formulation of ibuprofen.
Control group
Active

Outcomes
Primary outcome [1] 294048 0
To compare the bioavailability of ibuprofen (as summarised by AUC0-t(ss), Cmax(ss) and Cmin(ss)) for the two formulations. All plasma samples will be assayed for ibuprofen using a fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 294048 0
Pre-dose samples on study days 1 to 4 and 15 and 18 and 0, 0.5, 1, 2, 3, 4.0, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 20.0 and 24.0 hours on study days 5 and 19
Secondary outcome [1] 312414 0
Time to maximum peak concentration (Tmax) and the elimination half life (t1/2). Tmax will be the time where the maximum concentration occurred in the sample points. T1/2 = 0.693/Kel where kel is the terminal elimination rate constant.
Timepoint [1] 312414 0
Pre-dose samples on study days 1 to 4 and 15 and 18 and 0, 0.5, 1, 2, 3, 4.0, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 20.0 and 24.0 hours on study days 5 and 19

Eligibility
Key inclusion criteria
Healthy males and non-pregnant females
Aged between 18 and 55
Non-smoker
BMI between 18 and 33
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind excluding prescribed hormonal contraceptives
Who have received an investigational compound or drug known to induce or inhibit liver enzymes within 60 days of the start of the study
History or family history of depression or other mental illness, epilepsy or seizures
Sensitivity to ibuprofen, any NSAID medicines, excipients of ibuprofen
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are breastfeeding or are planning to start a family within 60 days of dosing
Who are planning on having any surgical or dental procedures within 4 weeks of the study completion
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood in the 60 days preceding the study.
Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identification of each treatment will only be known to the Managing Director and the Section Head - Trials and Regulatory Affairs.

Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation list will be prepared using a computer program for a balanced two-way crossover design.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
20/01/2015
Actual
22/01/2015
Date of last participant enrolment
Anticipated
Actual
22/01/2015
Date of last data collection
Anticipated
Actual
Sample size
Target
24
Accrual to date
Final
24
Recruitment outside Australia
Country [1] 6599 0
New Zealand
State/province [1] 6599 0
Otago

Funding & Sponsors
Funding source category [1] 290587 0
Commercial sector/Industry
Name [1] 290587 0
Generic Partners Pty Ltd
Country [1] 290587 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corporation Limited
Address
156 Frederick Street
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 289277 0
None
Name [1] 289277 0
Address [1] 289277 0
Country [1] 289277 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292225 0
Northern A Health & Disability Ethics Committee
Ethics committee address [1] 292225 0
Ethics committee country [1] 292225 0
New Zealand
Date submitted for ethics approval [1] 292225 0
Approval date [1] 292225 0
30/10/2014
Ethics approval number [1] 292225 0
14/NTA/161

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 54182 0
Dr Noelyn Hung
Address 54182 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 54182 0
New Zealand
Phone 54182 0
+6434779669
Fax 54182 0
+6434779605
Email 54182 0
noelyn.hung@otago.ac.nz
Contact person for public queries
Name 54183 0
Linda Folland
Address 54183 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 54183 0
New Zealand
Phone 54183 0
+6434779669
Fax 54183 0
+6434779605
Email 54183 0
linda.folland@zenithtechnology.co.nz
Contact person for scientific queries
Name 54184 0
Cheung-Tak Hung
Address 54184 0
Zenith Technology Corporation Limited 156 Frederick Street (PO Box 1777) Dunedin 9016
Country 54184 0
New Zealand
Phone 54184 0
+6434779669
Fax 54184 0
+6434779605
Email 54184 0
tak.hung@zenithtechnology.co.nz

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.